0001213900-22-006916.txt : 20220211 0001213900-22-006916.hdr.sgml : 20220211 20220211142315 ACCESSION NUMBER: 0001213900-22-006916 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220211 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUCELL CORP /DE/ CENTRAL INDEX KEY: 0000811641 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010382980 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12934 FILM NUMBER: 22619405 BUSINESS ADDRESS: STREET 1: 56 EVERGREEN DR CITY: PORTLAND STATE: ME ZIP: 04103 BUSINESS PHONE: 2078782770 MAIL ADDRESS: STREET 1: 56 EVERGREEN DRIVE CITY: PORTLAND STATE: ME ZIP: 04103 8-K 1 ea155463-8k_immucell.htm CURRENT REPORT
0000811641 false 0000811641 2022-02-11 2022-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) February 11, 2022

 

ImmuCell Corporation
(Exact name of registrant as specified in its charter)

 

DE   001-12934   01-0382980
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

56 Evergreen Drive Portland, Maine   04103
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code 207-878-2770

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.10 par value per share   ICCC   Nasdaq

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

  

 

 

 

 

 

Item 1.01 – Entry into a Material Definitive Agreement

 

Item 5.02.  Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On February 11, 2022, Dr. Joseph H. Crabb resigned from all positions he held at the Company, including without limitation as an employee and an officer of the Company. At the same time, the Company engaged Dr. Crabb as a consultant and advisor to the President of the Company. The Company has agreed to compensate Dr. Crabb with a payment of $70,000 when the Company receives all FDA approvals needed for the commencement of sales of Re-Tain® if certain other conditions are met. Dr. Crabb was recognized and thanked for all of his efforts discovering and developing the First Defense® and Re-Tain® technologies since he joined the Company in 1988.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d) Exhibits.

 

The Exhibits included as part of this Current Report on Form 8-K are listed in the Exhibit Index that follows.

 

The Exhibit Index and the Exhibits listed therein are incorporated herein by this reference.

 

 1 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUCELL CORPORATION
   
Date: February 11, 2022 By: /s/ Michael F. Brigham
    Michael F. Brigham
    President, Chief Executive Officer and Principal Financial Officer

 

 2 

 

 

Exhibit Index

 

Exhibit No.   Description
99.1   Independent Contractor Agreement between the Company and Joseph H. Crabb dated as of February 11, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 3 

 

 EX-99.1 2 ea155463ex99-1_immucell.htm INDEPENDENT CONTRACTOR AGREEMENT BETWEEN THE COMPANY AND JOSEPH H. CRABB DATED AS OF FEBRUARY 11, 2022

Exhibit 99.1

 

INDEPENDENT CONTRACTOR AGREEMENT

 

This Independent Contractor Agreement (“Agreement”) is made and effective as of February 11, 2022 between Joseph Crabb (“Consultant”) and ImmuCell Corporation, a Delaware corporation (“Company”).

 

Now, therefore, Consultant and Company agree as follows:

 

1. Resignation; Engagement.

 

Consultant hereby resigns, effective 11:59 P.M. on February 11, 2022, from all positions held by Consultant with Company, including without limitation as an employee and an officer of Company. Company hereby engages Consultant, and Consultant accepts the engagement, to act as a consultant and advisor to the President of Company and such other Company personnel and agents as the President may from time to time designate with respect to product development initiatives of Company (including without limitation the regulatory approval processes applicable to Company’s Re-Tain® mastitis product) for the term set forth in Section 2 hereof.

 

2. Term; Termination.

 

Consultant shall provide consulting services to Company pursuant to this Agreement for a term commencing on February 12, 2022 and ending on the earlier of (a) April 30, 2023 or (b) the receipt of the FDA approvals described in Section 4 hereof, unless earlier terminated as provided herein. Company shall be entitled to terminate this Agreement as provided in Section 3 hereof or in the event that Consultant breaches this Agreement and such breach, if capable of cure, is not cured within fifteen (15) days after receipt by Consultant of written notice thereof, in which case Company shall have no further liability to Consultant for compensation pursuant to Section 4 hereof or otherwise.

 

3. Time.

 

Consultant’s schedule and hours worked under this Agreement shall be subject to the reasonable discretion of the President of Company, in consultation with the Consultant, subject to Consultant’s reasonable prior personal and other commitments and obligations. Company relies upon Consultant to devote sufficient time as is reasonably necessary to effectively perform the services contemplated hereby. If Consultant’s availability is not sufficient, in the judgment of the President of Company, Company may provide written notice thereof to Consultant and, if a written schedule and availability commitment reasonably satisfactory to the President of Company is not achieved within fifteen (15) days of such notice, Company may terminate this Agreement with no further liability to Consultant for compensation pursuant to Section 4 hereof or otherwise.

 

4. Compensation.

 

Company agrees to pay to Consultant $70,000 when Company receives all FDA approvals needed for the commencement of sales of its Nisin (Re-Tain®) product in the United States (including final NADA approval), provided, however, that such payment shall be due and payable only if Consultant is a consultant to Company under this Agreement at the time of receipt of all such FDA approvals. The applicable payment shall be made within thirty days (30) days of receipt of such FDA approvals, and shall be subject to all required tax withholdings.

 

 

 

 

In addition, if Company undergoes a Change of Control or sells or licenses all or substantially all of the rights to manufacture and sell its Nisin product, and at the time of such Change of Control, sale or license Consultant is a consultant to Company under this Agreement, Company will make the payment to Consultant described in the first paragraph of this Section 4. For purposes hereof, “Change of Control” means (a) the sale of all or substantially all of Company’s assets, or (b) the sale or issuance of capital stock of Company, in a single transaction or series of related transactions, or a merger, consolidation or similar transaction to which Company is party, the result of which is one or more persons or entities acting together directly or indirectly acquiring a majority of the outstanding capital stock of Company or of the surviving or resulting entity in such transaction. For purposes hereof, a license of all or substantially all of the rights to manufacture and sell Company’s Nisin product shall not include a transaction in which Company continues to perform manufacturing services to or for the benefit of the licensee.

 

5. Independent Contractor.

 

Consultant shall be an independent contractor and not an employee, partner or agent of Company during the term set forth in Section 2 hereof. During such term, Consultant shall not be entitled to nor receive any benefit normally provided to Company’s employees such as, but not limited to, vacation payment, retirement, health care or sick pay. Consultant shall be solely responsible for filing all returns and paying any income, social security or other tax levied upon or determined with respect to any payment made to Consultant pursuant to this Agreement.

 

6. Confidential Information.

 

Consultant understands and acknowledges that during and prior to the term of this Agreement, he has had and will have access to and learn about Confidential Information, as defined below.

 

(a.) Definition. For purposes of this Agreement, “Confidential Information” means confidential, secret and proprietary documents, materials, data and other information, in tangible and intangible form, of and relating to Company and its business and existing and prospective customers, suppliers, investors and other associated third parties.

 

Confidential Information shall not include information that is generally available to and known by the public at the time of disclosure to Consultant or becomes publicly known or available thereafter; provided that such disclosure is through no direct or indirect fault of Consultant or person(s) acting on Consultant’s behalf.

 

(b.) Company Creation and Use of Confidential Information. Consultant understands and acknowledges that Company has invested, and continues to invest, substantial time, money and specialized knowledge into designing, manufacturing and selling products and maintaining and expanding its customer base. Consultant understands and acknowledges that as a result of these efforts, Company has created, and continues to use and create, Confidential Information. This Confidential Information provides Company with a competitive advantage over others in the marketplace.

 

2

 

 

(c.) Disclosure and Use Restrictions. Consultant agrees and covenants: (i) to treat all Confidential Information as strictly confidential; (ii) not to directly or indirectly disclose, publish, communicate or make available Confidential Information, or allow it to be disclosed, published, communicated or made available, in whole or part, to any entity or person whatsoever (including employees or consultants of Company) not having a need to know and authority to know and use the Confidential Information in connection with the business of Company and, in any event, not to anyone outside of the direct employ of Company except as required in the performance of Consultant’s authorized duties to Company (and then, such disclosure shall be made only within the limits and to the extent of such duties); and (iii) not to access or use any Confidential Information, and not to copy any documents, records, files, media or other resources containing any Confidential Information, or remove any such documents, records, files, media or other resources from the premises or control of Company, except as required in the performance of Consultant’s authorized duties to Company (and then, such disclosure shall be made only within the limits and to the extent of such duties). Nothing herein shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation or order. Consultant shall promptly provide written notice of any such order to the President of Company.

 

Consultant understands and acknowledges that his obligations under this Agreement with regard to any particular Confidential Information shall commence immediately upon Consultant first having access to such Confidential Information (whether before or after he begins to provide services under this Agreement to Company) and shall continue during and after his service to Company until such time as such Confidential Information has become public knowledge other than as a result of Consultant’s breach of this Agreement or breach by those acting in concert with Consultant or on Consultant’s behalf.

 

7. Restrictive Covenants.

 

(a.) Non-solicitation of Employees. Consultant agrees and covenants not to directly or indirectly solicit, hire, recruit, attempt to hire or recruit, or induce the termination of employment of any employee of Company during the twelve-month period, to run consecutively, beginning on the last day of Consultant’s consulting services to Company.

 

(b.) Non-disparagement. Each party agrees and covenants that he or it will not at any time make, publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the other party or his or its businesses, or any of his or its employees, officers, and existing and prospective customers, suppliers, investors and other associated third parties.

 

8. Remedies.

In the event of a breach or threatened breach by Consultant of Section 6 or 7 of this Agreement, Consultant hereby consents and agrees that Company shall be entitled to seek, in addition to other available remedies, a temporary or permanent injunction or other equitable relief against such breach or threatened breach from any court of competent jurisdiction, without the necessity of showing any actual damages or that money damages would not afford an adequate remedy, and without the necessity of posting any bond or other security. The aforementioned equitable relief shall be in addition to, not in lieu of, legal remedies, monetary damages or other available forms of relief.

 

3

 

 

9. Proprietary Rights.

 

(a.) Work Product. Consultant acknowledges and agrees that all writings, works of authorship, technology, inventions, discoveries, ideas and other work product of any nature whatsoever, that are created, prepared, produced, authored, edited, amended, conceived or reduced to practice by Consultant individually or jointly with others during the period of his employment by or his provision of consulting services to Company and relating in any way to the business or contemplated business of Company (regardless of when or where the Work Product is prepared or whose equipment or other resources is used in preparing the same) and all printed, physical and electronic copies, all improvements, rights and claims related to the foregoing, and other tangible embodiments thereof (collectively, “Work Product”), as well as any and all rights in and to copyrights, trade secrets, trademarks (and related goodwill), mask works, patents and other intellectual property rights therein arising in any jurisdiction throughout the world and all related rights of priority under international conventions with respect thereto, including all pending and future applications and registrations therefor, and continuations, divisions, continuations-in-part, reissues, extensions and renewals thereof (collectively, “Intellectual Property Rights”), shall be the sole and exclusive property of Company.

 

(b.) Work Made for Hire; Assignment. Consultant acknowledges that, by reason of being employed by or providing consulting services to Company at the relevant times, to the extent permitted by law, all of the Work Product consisting of copyrightable subject matter is “work made for hire” as defined in 17 U.S.C. § 101 and such copyrights are therefore owned by Company. To the extent that the foregoing does not apply, Consultant hereby irrevocably assigns to Company, for no additional consideration, Consultant’s entire right, title and interest in and to all Work Product and Intellectual Property Rights therein, including the right to sue, counterclaim and recover for all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding thereto throughout the world. Nothing contained in this Agreement shall be construed to reduce or limit Company’s rights, title or interest in any Work Product or Intellectual Property Rights so as to be less in any respect than that Company would have had in the absence of this Agreement.

 

(c.) Further Assurances; Power of Attorney. During and after his provision of consulting services to Company, Consultant agrees to reasonably cooperate with Company to (i) apply for, obtain, perfect and transfer to Company the Work Product as well as an Intellectual Property Right in the Work Product in any jurisdiction in the world; and (ii) maintain, protect and enforce the same, including, without limitation, executing and delivering to Company any and all applications, oaths, declarations, affidavits, waivers, assignments and other documents and instruments as shall be requested by Company. Consultant hereby irrevocably grants Company power of attorney to execute and deliver any such documents on Consultant’s behalf in his name and to do all other lawfully permitted acts to transfer the Work Product to Company and further the transfer, issuance, prosecution and maintenance of all Intellectual Property Rights therein, to the full extent permitted by law, if Consultant does not promptly cooperate with Company’s request (without limiting the rights Company shall have in such circumstances by operation of law). The power of attorney is coupled with an interest and shall not be affected by Consultant’s subsequent incapacity.

 

(d.) No License. Consultant understands that this Agreement does not, and shall not be construed to, grant Consultant any license or right of any nature with respect to any Work Product or Intellectual Property Rights or any Confidential Information, materials, software or other tools made available to him by Company.

 

4

 

 

10. Governing Law; Jurisdiction and Venue.

This Agreement, for all purposes, shall be construed in accordance with the laws of Maine without regard to conflicts of law principles. Any action or proceeding by either of the parties to enforce this Agreement or relating to any dispute arising under or in connection with this Agreement or the relationship between Consultant and Company shall be brought only in a state or federal court located in the state of Maine, county of Cumberland. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue.

 

11. Entire Agreement.

Unless specifically provided herein, this Agreement contains all of the understandings and representations between Consultant and Company pertaining to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter. The parties mutually agree that the Agreement can be specifically enforced in court and can be cited as evidence in legal proceedings alleging breach of the Agreement.

 

12. Modification and Waiver.

No provision of this Agreement may be amended or modified unless such amendment or modification is agreed to in writing and signed by Consultant and by the President of Company. No waiver by either of the parties of any breach by the other party hereto of any condition or provision of this Agreement to be performed by the other party hereto shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time, nor shall the failure of or delay by either of the parties in exercising any right, power or privilege hereunder operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such right, power or privilege.

 

13. Severability.

Should any provision of this Agreement be held by a court of competent jurisdiction to be enforceable only if modified, or if any portion of this Agreement shall be held as unenforceable and thus stricken, such holding shall not affect the validity of the remainder of this Agreement, the balance of which shall continue to be binding upon the parties with any such modification to become a part hereof and treated as though originally set forth in this Agreement.

 

The parties further agree that any such court is expressly authorized to modify any such unenforceable provision of this Agreement in lieu of severing such unenforceable provision from this Agreement in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Agreement or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law.

 

The parties expressly agree that this Agreement as so modified by the court shall be binding upon and enforceable against each of them. In any event, should one or more of the provisions of this Agreement be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, and if such provision or provisions are not modified as provided above, this Agreement shall be construed as if such invalid, illegal or unenforceable provisions had not been set forth herein.

 

5

 

14. Captions.

Captions and headings of the sections and paragraphs of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference to the caption or heading of any section or paragraph.

 

15. Counterparts.

This Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.

 

16. Successors and Assigns.

This Agreement is personal to Consultant and shall not be assigned by Consultant. Any purported assignment by Consultant shall be null and void from the initial date of the purported assignment. Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of Company. This Agreement shall inure to the benefit of Company and permitted successors and assigns.

 

17. Notices.

Notices and all other communications provided for in this Agreement shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested, or by overnight carrier to the parties at the addresses set forth below (or such other addresses as specified by the parties by like notice):

 

If to Company:

 

ImmuCell Corporation

56 Evergreen Drive

Portland, ME 04103

Attn: Michael F. Brigham, President and CEO

 

With a copy to:

Pierce Atwood LLP

254 Commercial Street

Portland, ME 04101

Attn: David J. Champoux, Esq.

 

If to Consultant:

 

Joseph Crabb

1292 Bemis Road

PO Box 746

Oquossoc, ME 04964

Email:

 

18. Survival.

Upon the expiration or other termination of this Agreement, the respective rights and obligations of the parties hereto shall survive such expiration or other termination to the extent necessary to carry out the intentions of the parties under this Agreement.

 

6

 

 

IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.

 

IMMUCELL CORPORATION   CONSULTANT
     
By:   /s/ Michael F. Brigham   Signature:   /s/ Joseph H. Crabb
Name:  Michael F. Brigham   Name: Joseph H. Crabb
Title:

President and CEO

      

 

 

7

 

 

 

 EX-101.SCH 3 iccc-20220211.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 iccc-20220211_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 iccc-20220211_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 11, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 11, 2022
Entity File Number 001-12934
Entity Registrant Name ImmuCell Corporation
Entity Central Index Key 0000811641
Entity Tax Identification Number 01-0382980
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 56 Evergreen Drive
Entity Address, City or Town Portland
Entity Address, State or Province ME
Entity Address, Postal Zip Code 04103
City Area Code 207
Local Phone Number 878-2770
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.10 par value per share
Trading Symbol ICCC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 ea155463-8k_immucell_htm.xml IDEA: XBRL DOCUMENT 0000811641 2022-02-11 2022-02-11 iso4217:USD shares iso4217:USD shares 0000811641 false 8-K 2022-02-11 ImmuCell Corporation DE 001-12934 01-0382980 56 Evergreen Drive Portland ME 04103 207 878-2770 false false false false Common Stock, $0.10 par value per share ICCC NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 122 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immucell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea155463-8k_immucell.htm ea155463ex99-1_immucell.htm iccc-20220211.xsd iccc-20220211_lab.xml iccc-20220211_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea155463-8k_immucell.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea155463-8k_immucell.htm" ] }, "labelLink": { "local": [ "iccc-20220211_lab.xml" ] }, "presentationLink": { "local": [ "iccc-20220211_pre.xml" ] }, "schema": { "local": [ "iccc-20220211.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ICCC", "nsuri": "http://immucell.com/20220211", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea155463-8k_immucell.htm", "contextRef": "From2022-02-11to2022-02-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://immucell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea155463-8k_immucell.htm", "contextRef": "From2022-02-11to2022-02-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://immucell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001213900-22-006916-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-006916-xbrl.zip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end